Description

Pentixafor is a synthetic cyclic pentapeptide derived from SDF-1 (CXCL12). Engineered to target the chemokine receptor CXCR4, which plays a pivotal role in tumor progression and metastasis, Pentixafor offers high-affinity binding in experimental models. This peptide enables visualization and investigation of CXCR4 expression, aiding in research across oncology, inflammation, and imaging agent development for PET tracers or therapeutic conjugates.

Product Specifications

Mechanism of Action & Research Applications

Pentixafor binds specifically to the CXCR4 receptor, which is overexpressed in many cancers and indicates disease aggressiveness. Its strong affinity makes it ideal for:

• Investigating CXCR4 expression in tumor biology

• Development of PET imaging agents for CXCR4-positive malignancies

• Studying CXCR4-mediated signaling and metastasis

• Building theranostic platforms combining diagnostics and CXCR4-targeted therapies

Side Effects (For Research Context Only)

In experimental models, Pentixafor may impact:

• Dynamics of receptor internalization in cellular assays

• Pharmacokinetics of imaging or therapeutic conjugates in vivo

• Receptor competition studies when combined with other ligands in molecular assays

Disclaimer

 is intended solely for laboratory research use and is not approved for clinical, diagnostic, or therapeutic applications.